Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 41.84B | 40.65B | 34.07B | 31.97B | 27.77B | 19.42B |
Gross Profit | 4.78B | 4.74B | 4.33B | 3.93B | 3.28B | 2.68B |
EBITDA | 1.90B | 1.89B | 1.74B | 1.35B | 1.13B | 1.15B |
Net Income | 1.18B | 1.18B | 1.09B | 792.00M | 659.00M | 673.00M |
Balance Sheet | ||||||
Total Assets | 13.37B | 15.63B | 14.89B | 12.31B | 12.21B | 9.53B |
Cash, Cash Equivalents and Short-Term Investments | 8.36B | 8.99B | 9.11B | 7.50B | 7.64B | 6.03B |
Total Debt | 2.38B | 3.12B | 2.38B | 2.39B | 2.39B | 2.35B |
Total Liabilities | 10.08B | 11.13B | 10.68B | 9.35B | 9.58B | 7.44B |
Stockholders Equity | 3.29B | 4.50B | 4.21B | 2.96B | 2.63B | 2.10B |
Cash Flow | ||||||
Free Cash Flow | 525.00M | 544.00M | 1.58B | 682.00M | 2.04B | 1.82B |
Operating Cash Flow | 620.00M | 644.00M | 1.66B | 773.00M | 2.12B | 1.89B |
Investing Cash Flow | -99.00M | -464.00M | -744.00M | -790.00M | -1.65B | -400.00M |
Financing Cash Flow | -138.00M | -347.00M | -58.00M | -441.00M | -183.00M | 225.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $12.17B | 10.61 | 18.35% | 0.42% | 9.73% | 51.87% | |
72 Outperform | $12.95B | 11.54 | 26.72% | ― | 16.71% | 12.23% | |
71 Outperform | $28.19B | 5.03 | 12.59% | ― | 8.85% | 33.30% | |
71 Outperform | $16.00B | 11.39 | 38.12% | ― | -1.79% | -41.85% | |
66 Neutral | $11.08B | 14.11 | 260.92% | ― | 5.11% | 14.28% | |
50 Neutral | kr5.39B | 12.66 | -80.61% | 5.12% | 37.36% | 27.71% | |
41 Neutral | $3.07B | ― | -30.57% | ― | ― | -147.80% |
On April 30, 2025, Molina Healthcare held its Annual Meeting where 85.6% of the company’s outstanding shares were represented. During the meeting, stockholders voted on several proposals, including the election of nine directors, approval of executive compensation, ratification of Ernst & Young LLP as the independent auditor, approval of the 2025 Equity Incentive Plan, and a stockholder proposal regarding special meetings. Key outcomes included the election of directors and the approval of the equity plan, while the executive compensation proposal faced significant opposition.